Bioxytran (BIXT) Non Operating Income (2010 - 2026)
Bioxytran (BIXT) posted Non Operating Income of -$135936.0 for Q1 2026, down 259.68% sequentially from $85130.0 in Q4 2025, and up 83.79% YoY from -$73963.5 in Q1 2025.
Bioxytran (BIXT) Non Operating Income (2010 - 2026) Analysis & Trends
Bioxytran has reported Non Operating Income for 16 years, with the latest figure at -$135936.0 in Q1 2026.
- Quarterly Non Operating Income rose 83.79% year-over-year to -$135936.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $421989.0 (up 135.14% YoY) and the FY2025 annual result came in at -$280568.0, down 78.78% from the prior year.
- Non Operating Income retreated to -$135936.0 in Q1 2026 per BIXT's latest filing, from $85130.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $259516.0 in Q2 2025 and troughed at -$838493.0 in Q1 2025.
- A 5-year average of -$86723.0 and a median of -$67735.0 in 2023 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 595.97% in 2025, down 508.26% in 2025.
- Over 5 years, Non Operating Income stood at $228505.0 in 2022, then slumped by 171.05% to -$162344.0 in 2023, then plunged by 62.51% to -$263825.0 in 2024, then soared by 132.27% to $85130.0 in 2025, then plunged by 259.68% to -$135936.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$135936.0, $85130.0, and $213279.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | 34,671.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -135,936.00 |
| Dec 31, 2025 | 85,130.00 |
| Sep 30, 2025 | 213,279.00 |
| Jun 30, 2025 | 259,516.00 |
| Mar 31, 2025 | -838,493.00 |
| Dec 31, 2024 | -263,825.00 |
| Sep 30, 2024 | -46,170.00 |
| Jun 30, 2024 | -52,325.00 |
| Mar 31, 2024 | 205,383.00 |
| Dec 31, 2023 | -162,344.00 |
| Sep 30, 2023 | -50,504.00 |
| Jun 30, 2023 | -390,302.00 |
| Mar 31, 2023 | -67,735.00 |
| Dec 31, 2022 | 228,505.00 |
| Sep 30, 2022 | -217,374.00 |
| Jun 30, 2022 | -96,816.00 |
| Mar 31, 2022 | -144,280.00 |
| Dec 31, 2021 | -62,439.00 |
| Sep 30, 2021 | -62,439.00 |
| Jun 30, 2021 | -101,320.00 |